Mycophenolic acid and cancer risk in solid organ transplant recipients: Systematic review and meta‐analysis

Pannaphak Hirunsatitpron,Nutthiya Hanprasertpong,Kajohnsak Noppakun,Dumnoensun Pruksakorn,Supanimit Teekachunhatean,Nut Koonrungsesomboon
DOI: https://doi.org/10.1111/bcp.14979
2021-07-29
British Journal of Clinical Pharmacology
Abstract:AimMycophenolic acid (MPA) is an immunosuppressive drug commonly used for prophylaxis of graft rejection in solid organ transplant recipients. The main concern with the prolonged use of immunosuppressive drugs is the risk of developing cancer. However, it remains unclear whether the immunosuppressive regimens containing MPA confer an increased degree of cancer risk. The present study aimed to determine the association between MPA exposure and the incidence of cancer in solid organ transplant recipients. MethodsA systematic search was performed on PubMed, EMBASE, and Cochrane Library. Relevant articles that have the findings on the incidence (or event) of cancer in cohorts with and without MPA exposure were retrieved for data extraction. A meta-analysis was conducted by means of the random-effects model, and the relative risk (RR) and its 95% confidence interval (95%CI) was used as a summary effect measure. ResultsA total of 39 studies were eligible for inclusion, with 32 studies that enabled meta-analysis. MPA exposure was significantly associated with a lower risk of cancer when compared to azathioprine exposure (RR = 0.66, 95%CI = 0.53-0.81, p <0.001) or no exposure to any additional treatments (RR = 0.85, 95%CI = 0.73-0.99, p = 0.04). No significant difference in cancer risk for the comparison between MPA exposure and mTOR inhibitor exposure (RR = 1.54, 95%CI = 0.96-2.46, p = 0.07). ConclusionsMPA exposure was not associated with an increased risk of cancer and may even be associated with a lower risk of cancer when compared to azathioprine or no treatment.
pharmacology & pharmacy
What problem does this paper attempt to address?